Genome & Company (KOSDAQ:314130)

Genome & Company Revenue

Genome & Company had revenue of 5.78B KRW in the quarter ending March 31, 2026, a decrease of -8.99%. This brings the company's revenue in the last twelve months to 24.02B, down -19.51% year-over-year. In the year 2025, Genome & Company had annual revenue of 24.59B, down -11.38%.

• Revenue (ttm): 24.02B
• Revenue Growth: -19.51%
• P/S Ratio: 10.05
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 241.42B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	24.59B	-3.16B	-11.38%
Dec 31, 2024	27.74B	13.45B	94.07%
Dec 31, 2023	14.30B	211.39M	1.50%
Dec 31, 2022	14.08B	13.63B	3,021.27%
Dec 31, 2021	451.25M	300.66M	199.67%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 13, 2026

Data Sources Report a data error